Aspectos epidemiológicos de la enfermedad cerebrovascular en el hospital de Caibarién. Cuba (página 2)

35.  Sacco RL ,Ellenberg JH, Mohr JP, et al: Infarcts of undetermined cause: The NINCDS Stroke Data Bank, Ann Neurol 25(4):382-390, 1989.

36.  Reed DM: The paradox of high risk of stroke in populations with low risk of coronar y heart disease, Am J Epidemiol 131(4):579-588, 1990.

37. Kase CS, Wolf PA, Chodosh EH, et al: Prevalence of silent stroke in patients presenting with initial stroke : The Framingham Study, Stroke 20( 7):850- 852, 1989.

38. Giele JL, Witkamp TD, Mali WP, et al: Silent brain infarcts in patients with manifest vascular disease, Stroke 35(3):742-746, 2004.

39.  Sacco RL, Foulke s MA, Mohr JP, et al: Determinants of early recurrence of cerebr al infarction. TheStroke Data Bank, Stroke 20(8):983-989, 1989.

40.  Goldstein L B, Adams R, Alberts MJ, et al: Primary prevention of ischemic stroke : A guideline from the American Heart Association/American Stroke Association Stroke Council, Stroke 37:1583-1633, 2006.

41.  Grundy SM, Pasternak R, Greenland P, et al: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology, J Am CollCardiol 34:1348-1359, 1999.

42. Wilson PWF, D"Agostino R B, Lev y D, et al: Prediction of coronary heart disease using risk factor categories, Circulation 97:1837-1847, 1998.

43. Wolf PA, D"Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: A risk profile from the Framingham Study, Stroke 22:312-318, 1991.

44. D"Agostino RB, Wolf PA, Belanger AJ, Kannel WB: Stroke risk profile: adjustment for antihypertensive medication. TheFraminghamStudy, Stroke 25:40-43, 1994.

45. D"Agostino RB, Vasan RS, Pencina MJ, et al: General cardiovascular risk profile for use in primary care: The Framingham Heart Study, Circulation 117:743-753, 2008.

46.  Fiore MC: U.S. Public Health Service Clinical Practice Guideline: treating tobacco use and dependence, Respir Care 45:1200-1262, 2000.

47. Galanti L M: Tobacco smoking cessation management: Integrating varenicline in current practice, Vasc Health Risk Manag 4:837-845, 2008.

48.  Stead LF, Perera R, Bullen C, et al: Nicotine replacement therapy for smoking cessation, Cochrane Database Syst Rev 23, 2008:CD000146.

49. McCar thy DE, Piasecki TM, Lawrence DL, et al: A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling, Nicotine Tob Res 10:717-729, 2008.

50. Aubin H-J, Bobak A, Br itton JR, et al: Vareniclineversus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial, Thorax 63:717-724, 2008.

51. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of c ardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials, Arch Intern Med 166:2307-2313, 2006.

52. O"Regan C, Wu P, Arora P, et al: Statin therapy in stroke prevention: A meta-analysis involving 121,000 patients, Am J Med 121:24-33, 2008.

53.  Rash A ,Downes T, Portner R, et al: A randomised controlled trial of warfarin versus aspirin for stroke pr eve ntion in octogenarians with atrial fibrillation (WASPO), Age Ageing 36:151-156, 2007.

54. Mant J, Hobbs FD, Fletcher K, et al: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomisedcontrolled trial, Lancet 370:493-503, 2007.

55. Hayden M, Pigone M, Phillips C, Mulrow C: Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Service s Task Force, Ann Intern Med 136:161-172, 2002.

56. Antiplatelet Trialists" Collaboration: Collaborative over view of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categorie of patients, BMJ 308:81-106, 1994.

57. Suárez Zaldivar R, Castillo Alarcón Y, Suárez Díaz, D y Suárez Díaz, M. Enfermedades cerebrovasculares: algunos aspectos clínicos patológicos. Hospital Ernesto Guevara, Las Tunas año 2008.

58. Flores Podadera H. Comportamiento de la enfermedad cerebrovascular en la Unidad de Cuidado Intensivo del municipio Centro Habana. [tesis].Hospital Clínico Quirúrgico Hermanos Ameijeiras: ECIMED; 2005.

59. Bembibre R, Soto A, Díaz D, Hernández A, Epidemiología de ECV hemorrágica en la región central de Cuba. Ver Neuro. 2004;33:601-4.

60. Instituto Nacional de Neurología. Estudio Nacional de Enfermedad Cerebrovascular. Grupo Nacional de Enfermedad Cerebrovascular. La Habana: Ministerio de Salud Pública; 2000.

61. Enríquez S. Lourdes. Enfermedad cerebrovascular aguda. Comportamiento en el Hospital Docente Dr. "Salvador Allende" año 2004.

62. Turrent J. Comportamiento y Manejo de la enfermedad cerebrovascular en una Unidad de cuidados Intensivos. Revista Cubana de Medicina Intensiva y Emergencias. [Seriado en Internet]. 2004 [citado 21 enero 2013]; 3(2): [aprox. 18 p.]. Disponible en: http://bvs.sld.cu

63. Láinez JM, Pareja A; Santonja JM. Estancia hospitalaria en la hemorragiasintracerebrales. RevNeurol 2009; 25(143): 1121-25.

64. Morales Rigau JM, garrote Rodríguez I, AchiongEstupiñán F, Fernández Alfonso J, delgado L, Rodríguez Jiménez P, et al. Mortalidad por enfermedad cerebrovasculares. Matanzas 1989-2006. Revista Médica Electrónica, Disponible en http:www.revmatanzas.sld.cu.

65. Beguería Santos R, Olivera Leal I, Álvarez Santana R, Flores Podadera Y, Baños Podadera H. Comportamiento de la mortalidad por enfermedad cerebrovascular en pacientes hipertensos. RevHabanCiencMéd La Habana. [Seriado en Internet].2008 Disponible en http://ucmh.sld.cu/.

66. Céspedes Fernández PL, Díaz Martínez A, Díaz Martínez C, Ruiz Ropero O, Bordies Hernández F. Morbi-Mortalidad por Enfermedad Cerebrovascular Hemorrágica. Guantánamo. 2000-2004. [tesis]. 2005. Hospital General Docente. Guantánamo.